| Literature DB >> 29190740 |
Jeneen Panezai1,2, Ambereen Ghaffar3, Mohammad Altamash1, Karl-Gösta Sundqvist4, Per-Erik Engström2, Anders Larsson5.
Abstract
BACKGROUND: Periodontal disease (PD) is characterized by inflammatory tissue destruction in tooth supporting apparatus. Many studies indicate that the underlying pathogenesis is in concordance with rheumatoid arthritis (RA) sharing immune-inflammatory events affect both diseases. The aim of this study was to investigate serum cytokines, chemokines, growth factors, enzymes and costimulatory proteins in association with periodontal conditions in PD and RA subjects. MATERIALS &Entities:
Mesh:
Substances:
Year: 2017 PMID: 29190740 PMCID: PMC5708747 DOI: 10.1371/journal.pone.0188945
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Biomarkers* with ≥ 60% of results included in the analyses.
| Adenosine Deaminase (ADA) | Interleukin-10 receptor subunit alpha (IL-10RA) |
| Beta-nerve growth factor (Beta-NGF) | Interleukin-10 receptor subunit beta (IL-10RB) |
| Caspase 8 (CASP-8) | Interleukin-12 subunit beta (IL-12B) |
| C-C motif chemokine 2 (CCL2) “MCP-1” | Interleukin-15 receptor subunit alpha (IL-15RA) |
| C-C motif chemokine 3 (CCL3) “MIP-1 alpha” | Interleukin-18 (IL-18) |
| C-C motif chemokine 4 (CCL4) | Interleukin-18 receptor 1 (IL-18R1) |
| C-C motif chemokine 7 (CCL7) “MCP-3” | Latency-associated peptide transforming growth factor beta 1 (LAP TGF-beta-1) |
| C-C motif chemokine 8 (CCL8) “MCP-2” | Leukemia inhibitory factor receptor (LIF-R) |
| C-C motif chemokine 11 (CCL11) “Eotaxin” | Macrophage colony-stimulating factor 1 (CSF-1) |
| C-C motif chemokine 13 (CCL13) “MCP-4” | Matrix metalloproteinase-1 (MMP-1) |
| C-C motif chemokine 19 (CCL19) | Matrix metalloproteinase-10 (MMP-10) |
| C-C motif chemokine 20 (CCL20) | Natural killer cell receptor 2B4 (CD244) |
| C-C motif chemokine 23 (CCL23) | Neurotrophin-3 (NT-3) |
| C-C motif chemokine 25 (CCL25) | Oncostatin-M (OSM) |
| C-C motif chemokine 28 (CCL28) | Osteoprotegerin (OPG) |
| CD40L receptor (CD40) | Programmed cell death 1 ligand 1 (PD-L1) |
| CUB domain-containing protein 1 (CDCP1) | Protein S100-A12 (EN-RAGE) |
| C-X-C motif chemokine 1 (CXCL1) | Signaling lymphocytic activation molecule (SLAMF1) |
| C-X-C motif chemokine 5 (CXCL5) | SIR2-like protein 2 (SIRT2) |
| C-X-C motif chemokine 6 (CXCL6) | STAM-binding protein (STAMPB) |
| C-X-C motif chemokine 8 (CXCL8) “IL-8” | Stem cell factor (SCF) |
| C-X-C motif chemokine 9 (CXCL9) | Sulfotransferase 1A1 (ST1A1) |
| C-X-C motif chemokine 10 (CXCL10) | T-cell surface glycoprotein CD5 (CD5) |
| C-X-C motif chemokine 11 (CXCL11) | T cell surface glycoprotein CD6 isoform (CD6) |
| C-X3-C motif chemokine ligand 1(CX3CL1) “Fractalkine” | TNF-beta (TNFB) |
| Cystatin D (CST5) | TNF-related activation-induced cytokine (TRANCE) |
| Delta and Notch-like epidermal growth factor-related receptor (DNER) | TNF-related apoptosis-inducing ligand (TRAIL) |
| Fibroblast growth factor 19 (FGF-19) | Transforming growth factor alpha (TGF-alpha) |
| Fms-related tyrosine kinase 3 ligand (Flt3L) | Tumor necrosis factor (Ligand) superfamily, member 12 (TWEAK) |
| Hepatocyte growth factor (HGF) | Tumor necrosis factor ligand superfamily member 14 (TNFSF14) |
| Interleukin-6 (IL-6) | Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) |
| Interleukin-7 (IL-7) | Urokinase-type plasminogen activator (uPA) |
| Interleukin-10 (IL-10) | Vascular endothelial growth factor A (VEGF-A) |
*Common synonyms used in Olink inflammation Panel are shown in double inverted commas.
Characteristics of study group.
| Total subjects (n) | 90 |
| Mean age distribution in years (range) | 46.4 ± 10.1 (21–70) |
| Females (n, %) | 64 (71) |
| Total subjects with RA (n) | 38 |
| Subjects with RA and PD (n, %) | 19 (50) |
| Subjects with RA and without PD (n, %) | 19 (50) |
| Total subjects with PD only (n) | 38 |
| Healthy Controls (n) | 14 |
RA = rheumatoid arthritis PD = periodontal disease.
Characteristics of the rheumatoid arthritis (RA) group.
| Characteristic | RA without PD (n = 19) | RA with PD (n = 19) |
|---|---|---|
| Years since diagnosis | 8.7 | 8.1 |
| IgM-RF (≥30 IU/mL) | 117.5 | 168.7 |
| ESR (mm/hr) | 49.8 | 54.8 |
| Anti-CCP (≥ 3 U/mL) | 251.7 | 286.1 |
Values are shown as mean ± SD.
IU = international units
Anti-CCP values are expressed as arbitrary units (U/mL)
PD = periodontal disease
Clinical (BOP, PPD 3-<5mm, PPD ≥5mm, number of teeth) and radiographic (mandibular MBL) parameters in RA (with and without PD), PD and control groups.
| RA without PD | RA with PD | PD | Controls | |
|---|---|---|---|---|
| 42.6 ± 31 | 37 ± 32 | 76.2 ± 27 | 27.2 ± 29.4 | |
| 55.5 ± 16.2 | 43.5 ± 17.9 | 49.2 ± 17.4 | 26.9 ± 14.1 | |
| 0.32 ± 0.74 | 18.2 ± 15.2§ | 33.4 ± 14.1 | 0.4 ± 0.5 | |
| 26.8 ± 2.9 | 25.5 ± 4.1 | 24.8 ± 4.3 | 26.1 ± 4.7 | |
| 2.9 ± 1 | 3.8 ± 2.2 | 5.4 ± 2.6 | 3.3 ± 0.7 |
Differences in the means ± SD of clinical parameters were tested using one-way ANOVA. For multiple comparisons, post-hoc Tukey HSD test was performed.
* compared to RA without PD. P<0.01
‡ compared RA with PD. P<0.01
§ compared to healthy controls. P<0.01
** compared to healthy controls. P<0.05
BOP = Bleeding on probing, PPD = Probing pocket depth, MBL = marginal bone loss
RA = rheumatoid arthritis PD = periodontal disease
Correlation of cytokines with clinical parameters* using Spearman rank correlation.
The data is presented for biomarkers with adjusted p-values ≤ 0.05 considered significant after using the Benjamini and Hochberg procedure for multiple testing (n = 69).
| BOP | PPD 3 - <5mm | PPD ≥ 5mm | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DNER | -0.45 | 0.000 | 0.005 | CCL25 | -0.41 | 0.000 | 0.001 | DNER | -0.68 | 1.5E-10 | 0.003 |
| CD40 | -0.42 | 0.000 | 0.010 | TNFB | -0.41 | 0.000 | 0.003 | TWEAK | -0.63 | 5.6E-09 | 0.006 |
| ST1A1 | 0.41 | 0.000 | 0.015 | CCL28 | -0.41 | 0.001 | 0.004 | EN-RAGE | -0.59 | 7.3E-08 | 0.008 |
| FGF-19 | 0.39 | 0.001 | 0.020 | CXCL5 | -0.39 | 0.001 | 0.006 | ST1A1 | 0.59 | 9.2E-08 | 0.011 |
| EN-RAGE | -0.38 | 0.001 | 0.025 | LAP TGF-beta-1 | -0.39 | 0.001 | 0.007 | CX3CL1 | -0.57 | 3.4E-07 | 0.014 |
| NT-3 | 0.38 | 0.001 | 0.030 | CCL19 | -0.38 | 0.001 | 0.009 | FGF-19 | 0.55 | 1.0E-06 | 0.017 |
| CASP-8 | 0.34 | 0.004 | 0.035 | ADA | -0.38 | 0.001 | 0.010 | TNFRSF9 | -0.48 | 3.2E-05 | 0.019 |
| TWEAK | -0.32 | 0.007 | 0.040 | SCF | -0.36 | 0.002 | 0.012 | CCL8 | -0.40 | 7.7E-04 | 0.022 |
| CD244 | 0.28 | 0.018 | 0.045 | CXCL11 | -0.36 | 0.003 | 0.013 | NT-3 | 0.38 | 1.3E-03 | 0.025 |
| CX3CL1 | -0.25 | 0.036 | 0.050 | CD40 | 0.35 | 0.003 | 0.015 | STAMPB | -0.37 | 1.9E-03 | 0.028 |
| SIRT2 | -0.35 | 0.003 | 0.016 | LIF-R | 0.33 | 5.8E-03 | 0.031 | ||||
| CCL11 | -0.35 | 0.003 | 0.018 | CCL25 | 0.33 | 6.1E-03 | 0.033 | ||||
| CASP-8 | -0.34 | 0.004 | 0.019 | CD5 | 0.31 | 9.4E-03 | 0.036 | ||||
| IL-12B | -0.33 | 0.006 | 0.021 | CASP-8 | 0.31 | 9.7E-03 | 0.039 | ||||
| IL-10 | -0.32 | 0.007 | 0.022 | CD6 | 0.29 | 1.5E-02 | 0.042 | ||||
| SLAMF1 | -0.31 | 0.009 | 0.024 | SIRT2 | -0.28 | 1.8E-02 | 0.044 | ||||
| TRANCE | -0.31 | 0.009 | 0.025 | CCL20 | -0.26 | 3.3E-02 | 0.047 | ||||
| CXCL1 | -0.31 | 0.009 | 0.026 | CD40 | -0.25 | 3.6E-02 | 0.050 | ||||
| CXCL6 | -0.31 | 0.009 | 0.028 | ||||||||
| CCL4 | -0.30 | 0.011 | 0.029 | ||||||||
| TGFA | -0.30 | 0.011 | 0.031 | ||||||||
| CD244 | -0.29 | 0.014 | 0.032 | ||||||||
| TRAIL | -0.29 | 0.015 | 0.034 | ||||||||
| IL-10RB | -0.28 | 0.018 | 0.035 | ||||||||
| IL-7 | -0.28 | 0.019 | 0.037 | ||||||||
| CD6 | -0.28 | 0.019 | 0.038 | ||||||||
| MMP-10 | -0.27 | 0.023 | 0.040 | ||||||||
| MMP-1 | -0.27 | 0.024 | 0.041 | ||||||||
| CCL7 | -0.27 | 0.027 | 0.043 | ||||||||
| CCL3 | -0.26 | 0.028 | 0.044 | ||||||||
| CD5 | -0.26 | 0.034 | 0.046 | ||||||||
| Beta-NGF | -0.25 | 0.040 | 0.047 | ||||||||
| TNFRSF9 | -0.24 | 0.044 | 0.049 | ||||||||
*BOP = Bleeding on probing, PPD = Probing pocket depth
Correlation of cytokines with MBL* in mandibular molars and premolars and number of teeth using Spearman rank correlation.
The data is presented for biomarkers with adjusted p-values ≤ 0.05 considered significant after using the Benjamini and Hochberg procedure for multiple testing (n = 69).
| MBL | Number of Teeth | ||||||
|---|---|---|---|---|---|---|---|
| TWEAK | -0.52 | 4.3E-06 | 2.9E-03 | CDCP1 | -0.53 | 2.38E-06 | 0.002 |
| DNER | -0.51 | 6.8E-06 | 5.9E-03 | CCL8 | 0.51 | 6.59E-06 | 0.004 |
| CX3CL1 | -0.50 | 1.2E-05 | 8.8E-03 | STAMPB | 0.50 | 1.13E-05 | 0.006 |
| STAMPB | -0.50 | 1.3E-05 | 1.2E-02 | CX3CL1 | 0.50 | 1.37E-05 | 0.007 |
| EN-RAGE | -0.46 | 6.3E-05 | 1.5E-02 | TNFRSF9 | 0.44 | 1.84E-04 | 0.009 |
| FGF-19 | 0.46 | 7.2E-05 | 1.8E-02 | DNER | 0.40 | 6.29E-04 | 0.011 |
| CCL8 | -0.45 | 1.1E-04 | 2.1E-02 | SIRT2 | 0.38 | 1.37E-03 | 0.013 |
| TNFRSF9 | -0.45 | 1.2E-04 | 2.4E-02 | TWEAK | 0.36 | 2.56E-03 | 0.015 |
| CDCP1 | 0.37 | 2.0E-03 | 2.6E-02 | FGF-19 | -0.35 | 2.86E-03 | 0.017 |
| SIRT2 | -0.34 | 4.2E-03 | 2.9E-02 | EN-RAGE | 0.35 | 3.34E-03 | 0.019 |
| ST1A1 | 0.33 | 5.1E-03 | 3.2E-02 | CXCL10 | 0.34 | 3.87E-03 | 0.020 |
| HGF | 0.30 | 1.1E-02 | 3.5E-02 | CXCL11 | 0.31 | 8.54E-03 | 0.022 |
| NT-3 | 0.30 | 1.1E-02 | 3.8E-02 | CCL11 | 0.31 | 9.36E-03 | 0.024 |
| IL-10RA | -0.27 | 2.7E-02 | 4.1E-02 | VEGF-A | 0.30 | 1.36E-02 | 0.026 |
| MMP-10 | -0.25 | 3.7E-02 | 4.4E-02 | CCL4 | 0.30 | 1.38E-02 | 0.028 |
| CXCL10 | -0.25 | 4.0E-02 | 4.7E-02 | CCL20 | 0.28 | 2.07E-02 | 0.030 |
| CD6 | 0.25 | 4.1E-02 | 5.0E-02 | CXCL5 | 0.28 | 2.20E-02 | 0.031 |
| CXCL6 | 0.27 | 2.28E-02 | 0.033 | ||||
| MMP-1 | 0.27 | 2.53E-02 | 0.035 | ||||
| IL-10 | 0.27 | 2.63E-02 | 0.037 | ||||
| IL-7 | 0.27 | 2.68E-02 | 0.039 | ||||
| TGFA | 0.26 | 2.81E-02 | 0.041 | ||||
| ST1A1 | -0.26 | 3.43E-02 | 0.043 | ||||
| IL-18R1 | -0.25 | 3.45E-02 | 0.044 | ||||
| CCL23 | 0.25 | 3.82E-02 | 0.046 | ||||
| HGF | -0.24 | 4.34E-02 | 0.048 | ||||
| LAP TGF-beta-1 | 0.24 | 4.82E-02 | 0.050 | ||||
MBL = marginal bone loss
Correlation of cytokines with BOP, PPD 3-<5 and PPD ≥ 5mm in RA subjects with and without PD using Spearman rank correlation.
Adjusted p-values ≤ 0.05 considered significant after using the Benjamini and Hochberg procedure for multiple testing.
| RA WITH PD | RA WITHOUT PD | ||||||
|---|---|---|---|---|---|---|---|
| IL-7 | -0.67 | 0.002 | 0.002 | SLAMF1 | -0.47 | 0.044 | 0.017 |
| IL-10RB | -0.61 | 0.006 | 0.007 | ADA | -0.58 | 0.009 | 0.050 |
| CXCL10 | -0.60 | 0.006 | 0.009 | ||||
| uPA | -0.60 | 0.006 | 0.011 | ||||
| MMP-10 | -0.60 | 0.006 | 0.013 | ||||
| TGF-beta-1 | -0.60 | 0.007 | 0.015 | ||||
| TWEAK | -0.59 | 0.008 | 0.017 | ||||
| CX3CL1 | -0.57 | 0.011 | 0.020 | ||||
| Flt3L | 0.56 | 0.012 | 0.022 | ||||
| CXCL6 | -0.56 | 0.012 | 0.024 | ||||
| EN-RAGE | 0.56 | 0.013 | 0.026 | ||||
| CCL25 | -0.56 | 0.013 | 0.028 | ||||
| CXCL5 | -0.56 | 0.013 | 0.030 | ||||
| SCF | -0.55 | 0.016 | 0.033 | ||||
| FGF-19 | -0.54 | 0.017 | 0.035 | ||||
| CXCL1 | -0.52 | 0.022 | 0.037 | ||||
| SLAMF1 | -0.51 | 0.025 | 0.039 | ||||
| MMP-1 | -0.50 | 0.029 | 0.041 | ||||
| TRAIL | -0.49 | 0.033 | 0.043 | ||||
| CCL19 | -0.47 | 0.041 | 0.046 | ||||
| CD244 | -0.47 | 0.041 | 0.048 | ||||
| CCL8 | -0.75 | 0.000 | 0.001 | TGFA | -0.55 | 0.01 | 0.03 |
| PD-L1 | -0.72 | 0.000 | 0.003 | MMP-10 | -0.48 | 0.04 | 0.05 |
| CASP-8 | -0.70 | 0.001 | 0.004 | ||||
| CCL13 | -0.70 | 0.001 | 0.005 | ||||
| STAMPB | -0.70 | 0.001 | 0.007 | ||||
| CXCL11 | -0.70 | 0.001 | 0.008 | ||||
| CD244 | -0.69 | 0.001 | 0.009 | ||||
| CX3CL1 | -0.68 | 0.001 | 0.011 | ||||
| TNFB | -0.67 | 0.002 | 0.012 | ||||
| IL-15RA | -0.65 | 0.002 | 0.014 | ||||
| CCL2 | -0.64 | 0.003 | 0.015 | ||||
| CCL20 | -0.63 | 0.004 | 0.016 | ||||
| SLAMF1 | -0.62 | 0.005 | 0.018 | ||||
| CCL19 | -0.60 | 0.007 | 0.019 | ||||
| Beta-NGF | -0.60 | 0.007 | 0.020 | ||||
| IL-10RB | -0.59 | 0.008 | 0.022 | ||||
| IL-10 | -0.58 | 0.009 | 0.023 | ||||
| SIRT2 | -0.58 | 0.009 | 0.024 | ||||
| CXCL6 | -0.57 | 0.011 | 0.026 | ||||
| 4E-BP1 | -0.56 | 0.012 | 0.027 | ||||
| IL-10RA | -0.55 | 0.014 | 0.028 | ||||
| IL-12B | -0.55 | 0.015 | 0.030 | ||||
| MIP-1alpha | -0.54 | 0.018 | 0.031 | ||||
| IL-7 | -0.53 | 0.018 | 0.032 | ||||
| CXCL10 | -0.53 | 0.020 | 0.034 | ||||
| ADA | -0.53 | 0.020 | 0.035 | ||||
| CXCL1 | -0.52 | 0.022 | 0.036 | ||||
| CCL23 | -0.52 | 0.024 | 0.038 | ||||
| VEGF-A | -0.51 | 0.024 | 0.039 | ||||
| CXCL5 | -0.51 | 0.024 | 0.041 | ||||
| CCL4 | -0.51 | 0.027 | 0.042 | ||||
| uPA | -0.50 | 0.030 | 0.043 | ||||
| LIF-R | -0.49 | 0.032 | 0.045 | ||||
| CCL25 | -0.48 | 0.037 | 0.046 | ||||
| SCF | -0.48 | 0.038 | 0.047 | ||||
| FGF-19 | -0.47 | 0.044 | 0.049 | ||||
| NT-3 | -0.47 | 0.044 | 0.050 | ||||
| CXCL10 | -0.49 | 0.034 | 0.036 | ||||
| IL-10 | -0.46 | 0.048 | 0.050 | ||||
*BOP = Bleeding on probing, PPD = Probing pocket depth
RA = rheumatoid arthritis PD = periodontal disease
Correlation of cytokines with mandibular MBL* and number of teeth in RA subjects with and without PD using Spearman rank correlation.
Adjusted p-values ≤ 0.05 considered significant after using the Benjamini and Hochberg procedure for multiple testing.
| RA WITH PD | RA WITHOUT PD | ||||||
|---|---|---|---|---|---|---|---|
| CCL7 | 0.62 | 0.015 | 0.050 | ADA | 0.61 | 0.007 | 0.017 |
| CST5 | 0.57 | 0.013 | 0.033 | ||||
| SLAMF1 | 0.51 | 0.029 | 0.050 | ||||
| CCL7 | -0.52 | 0.022 | 0.025 | DNER | 0.46 | 0.049 | 0.050 |
| CXCL9 | -0.51 | 0.026 | 0.030 | ||||
| CD244 | -0.50 | 0.030 | 0.035 | ||||
| Flt3L | -0.48 | 0.040 | 0.040 | ||||
| IL-15RA | -0.47 | 0.044 | 0.045 | ||||
| CDCP1 | -0.46 | 0.048 | 0.050 | ||||
*MBL = marginal bone loss
RA = rheumatoid arthritis PD = periodontal disease